Is QDEL or NEOG more profitable?

Neogen has a net margin of -0.91% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -39.20% 4.88% 1.63% Neogen -0.91% 2.78% 1.74%

Does the media favor QDEL or NEOG?

In the previous week, Neogen had 6 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for Neogen and 2 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.23 beat Neogen's score of 0.66 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XRAY or QDEL?

In the previous week, DENTSPLY SIRONA had 2 more articles in the media than QuidelOrtho. MarketBeat recorded 4 mentions for DENTSPLY SIRONA and 2 mentions for QuidelOrtho. DENTSPLY SIRONA's average media sentiment score of 1.24 beat QuidelOrtho's score of 1.23 indicating that DENTSPLY SIRONA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DENTSPLY SIRONA 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QuidelOrtho 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QDEL or UFPT?

QuidelOrtho presently has a consensus target price of $13.63, suggesting a potential upside of 15.66%. Given QuidelOrtho's higher possible upside, equities analysts clearly believe QuidelOrtho is more favorable than UFP Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 UFP Technologies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend AVNS or QDEL?

QuidelOrtho has a consensus target price of $13.63, suggesting a potential upside of 15.66%. Given QuidelOrtho's higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 QuidelOrtho 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to AVNS or QDEL?

In the previous week, Avanos Medical had 1 more articles in the media than QuidelOrtho. MarketBeat recorded 3 mentions for Avanos Medical and 2 mentions for QuidelOrtho. Avanos Medical's average media sentiment score of 1.81 beat QuidelOrtho's score of 1.23 indicating that Avanos Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avanos Medical 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive QuidelOrtho 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, QDEL or CERS?

Cerus has lower revenue, but higher earnings than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio QuidelOrtho $2.73B 0.30 -$1.13B -$15.41 N/A Cerus $206.13M 2.43 -$15.63M -$0.03 N/A

Is QDEL or CERS more profitable?

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -39.20% 4.88% 1.63% Cerus -3.06% -10.19% -3.14%

Does the media favor QDEL or CERS?

In the previous week, QuidelOrtho and QuidelOrtho both had 2 articles in the media. Cerus' average media sentiment score of 1.77 beat QuidelOrtho's score of 1.23 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

QuidelOrtho (QDEL) Competitors

$11.78 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.92 +0.15 (+1.23%)

As of 09:04 AM Eastern

Compare

QDEL vs. NEOG, XRAY, UFPT, AVNS, and CERS

Should you buy QuidelOrtho stock or one of its competitors? QuidelOrtho's main competitors and comparable companies include Neogen (NEOG), DENTSPLY SIRONA (XRAY), UFP Technologies (UFPT), Avanos Medical (AVNS), and Cerus (CERS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does QuidelOrtho compare to Neogen?

QuidelOrtho (NASDAQ:QDEL) and Neogen (NASDAQ:NEOG) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by insiders. Comparatively, 0.5% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neogen had 6 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for Neogen and 2 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.23 beat Neogen's score of 0.66 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

QuidelOrtho has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Neogen has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

Neogen has lower revenue, but higher earnings than QuidelOrtho. Neogen is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.30	-$1.13B	-$15.41	N/A
Neogen	$870.40M	2.95	-$7.90M	-$0.03	N/A

Neogen has a net margin of -0.91% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Neogen	-0.91%	2.78%	1.74%

QuidelOrtho presently has a consensus price target of $13.63, suggesting a potential upside of 15.66%. Neogen has a consensus price target of $12.00, suggesting a potential upside of 1.87%. Given QuidelOrtho's higher possible upside, equities research analysts clearly believe QuidelOrtho is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Neogen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Neogen beats QuidelOrtho on 9 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to DENTSPLY SIRONA?

DENTSPLY SIRONA (NASDAQ:XRAY) and QuidelOrtho (NASDAQ:QDEL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

95.7% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

DENTSPLY SIRONA has a net margin of -14.99% compared to QuidelOrtho's net margin of -39.20%. DENTSPLY SIRONA's return on equity of 20.84% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DENTSPLY SIRONA	-14.99%	20.84%	5.32%
QuidelOrtho	-39.20%	4.88%	1.63%

DENTSPLY SIRONA has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

DENTSPLY SIRONA has higher revenue and earnings than QuidelOrtho. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DENTSPLY SIRONA	$3.68B	0.57	-$598M	-$2.75	N/A
QuidelOrtho	$2.73B	0.30	-$1.13B	-$15.41	N/A

In the previous week, DENTSPLY SIRONA had 2 more articles in the media than QuidelOrtho. MarketBeat recorded 4 mentions for DENTSPLY SIRONA and 2 mentions for QuidelOrtho. DENTSPLY SIRONA's average media sentiment score of 1.24 beat QuidelOrtho's score of 1.23 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DENTSPLY SIRONA	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DENTSPLY SIRONA presently has a consensus price target of $13.54, suggesting a potential upside of 29.43%. QuidelOrtho has a consensus price target of $13.63, suggesting a potential upside of 15.66%. Given DENTSPLY SIRONA's stronger consensus rating and higher possible upside, equities research analysts plainly believe DENTSPLY SIRONA is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DENTSPLY SIRONA	3 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

DENTSPLY SIRONA beats QuidelOrtho on 13 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to UFP Technologies?

QuidelOrtho (NASDAQ:QDEL) and UFP Technologies (NASDAQ:UFPT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, QuidelOrtho had 1 more articles in the media than UFP Technologies. MarketBeat recorded 2 mentions for QuidelOrtho and 1 mentions for UFP Technologies. QuidelOrtho's average media sentiment score of 1.23 beat UFP Technologies' score of 0.69 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Overall Sentiment
QuidelOrtho	Positive
UFP Technologies	Positive

UFP Technologies has a net margin of 11.45% compared to QuidelOrtho's net margin of -39.20%. UFP Technologies' return on equity of 18.42% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
UFP Technologies	11.45%	18.42%	11.96%

QuidelOrtho presently has a consensus target price of $13.63, suggesting a potential upside of 15.66%. Given QuidelOrtho's higher possible upside, equities analysts clearly believe QuidelOrtho is more favorable than UFP Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
UFP Technologies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 87.3% of UFP Technologies shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by company insiders. Comparatively, 4.6% of UFP Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

UFP Technologies has lower revenue, but higher earnings than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than UFP Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.30	-$1.13B	-$15.41	N/A
UFP Technologies	$602.80M	3.57	$68.31M	$9.28	29.95

QuidelOrtho has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, UFP Technologies has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Summary

UFP Technologies beats QuidelOrtho on 10 of the 15 factors compared between the two stocks.

How does QuidelOrtho compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Avanos Medical has higher earnings, but lower revenue than QuidelOrtho. Avanos Medical is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A
QuidelOrtho	$2.73B	0.30	-$1.13B	-$15.41	N/A

Avanos Medical has a net margin of -10.39% compared to QuidelOrtho's net margin of -39.20%. Avanos Medical's return on equity of 5.39% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
QuidelOrtho	-39.20%	4.88%	1.63%

In the previous week, Avanos Medical had 1 more articles in the media than QuidelOrtho. MarketBeat recorded 3 mentions for Avanos Medical and 2 mentions for QuidelOrtho. Avanos Medical's average media sentiment score of 1.81 beat QuidelOrtho's score of 1.23 indicating that Avanos Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avanos Medical	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
QuidelOrtho	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avanos Medical has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

QuidelOrtho has a consensus target price of $13.63, suggesting a potential upside of 15.66%. Given QuidelOrtho's higher probable upside, analysts clearly believe QuidelOrtho is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 2.3% of Avanos Medical shares are held by insiders. Comparatively, 1.1% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Avanos Medical beats QuidelOrtho on 10 of the 14 factors compared between the two stocks.

How does QuidelOrtho compare to Cerus?

QuidelOrtho (NASDAQ:QDEL) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

QuidelOrtho has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Cerus has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

In the previous week, QuidelOrtho and QuidelOrtho both had 2 articles in the media. Cerus' average media sentiment score of 1.77 beat QuidelOrtho's score of 1.23 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by company insiders. Comparatively, 5.3% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Cerus	-3.06%	-10.19%	-3.14%

Cerus has lower revenue, but higher earnings than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.30	-$1.13B	-$15.41	N/A
Cerus	$206.13M	2.43	-$15.63M	-$0.03	N/A

QuidelOrtho presently has a consensus price target of $13.63, indicating a potential upside of 15.66%. Cerus has a consensus price target of $5.25, indicating a potential upside of 110.84%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Cerus beats QuidelOrtho on 10 of the 15 factors compared between the two stocks.

Get QuidelOrtho News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QDEL vs. The Competition

Export

Metric	QuidelOrtho	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$807.76M	$5.40B	$7.15B	$12.84B
Dividend Yield	N/A	1.80%	2.57%	11.71%
P/E Ratio	-0.76	25.09	275.28	25.35
Price / Sales	0.30	71.63	646.14	90.72
Price / Cash	0.62	33.03	28.42	34.96
Price / Book	0.42	5.97	10.37	6.21
Net Income	-$1.13B	$150.75M	$3.50B	$358.54M
7 Day Performance	-15.68%	-2.75%	-3.30%	-2.39%
1 Month Performance	-17.62%	-3.35%	-0.86%	-3.39%
1 Year Performance	-58.77%	9.46%	23.53%	8.81%

QuidelOrtho Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QDEL QuidelOrtho	2.9565 of 5 stars	$11.78 flat	$13.63 +15.7%	-58.8%	$807.76M	$2.73B	N/A	6,500	Positive News Gap Up
NEOG Neogen	1.8224 of 5 stars	$11.83 flat	$12.00 +1.4%	+114.2%	$2.58B	$870.40M	N/A	2,110	Analyst Upgrade Gap Down
XRAY DENTSPLY SIRONA	4.1267 of 5 stars	$11.38 flat	$13.54 +19.0%	-22.7%	$2.27B	$3.68B	N/A	14,000
UFPT UFP Technologies	1.5068 of 5 stars	$288.79 flat	N/A	+39.4%	$2.24B	$602.80M	31.12	5,349
AVNS Avanos Medical	0.3519 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	2,287	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QDEL) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

QuidelOrtho (QDEL) Competitors

QDEL vs. NEOG, XRAY, UFPT, AVNS, and CERS

How does QuidelOrtho compare to Neogen?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Summary

How does QuidelOrtho compare to UFP Technologies?

Summary

How does QuidelOrtho compare to Avanos Medical?

Summary

How does QuidelOrtho compare to Cerus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

QuidelOrtho (QDEL) Competitors

QDEL vs. NEOG, XRAY, UFPT, AVNS, and CERS

How does QuidelOrtho compare to Neogen?

Do institutionals and insiders have more ownership in QDEL or NEOG?

Does the media favor QDEL or NEOG?

Which has more risk & volatility, QDEL or NEOG?

Which has stronger earnings & valuation, QDEL or NEOG?

Is QDEL or NEOG more profitable?

Do analysts prefer QDEL or NEOG?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Do insiders and institutionals hold more shares of XRAY or QDEL?

Is XRAY or QDEL more profitable?

Which has more volatility & risk, XRAY or QDEL?

Which has higher valuation and earnings, XRAY or QDEL?

Does the media refer more to XRAY or QDEL?

Do analysts prefer XRAY or QDEL?

Summary

How does QuidelOrtho compare to UFP Technologies?

Does the media favor QDEL or UFPT?

Is QDEL or UFPT more profitable?

Do analysts rate QDEL or UFPT?

Do insiders & institutionals have more ownership in QDEL or UFPT?

Which has higher valuation and earnings, QDEL or UFPT?

Which has more risk and volatility, QDEL or UFPT?

Summary

How does QuidelOrtho compare to Avanos Medical?

Which has preferable valuation & earnings, AVNS or QDEL?

Is AVNS or QDEL more profitable?

Does the media refer more to AVNS or QDEL?

Which has more volatility & risk, AVNS or QDEL?

Do analysts recommend AVNS or QDEL?

Do insiders & institutionals have more ownership in AVNS or QDEL?

Summary

How does QuidelOrtho compare to Cerus?

Which has more volatility and risk, QDEL or CERS?

Does the media favor QDEL or CERS?

Do institutionals and insiders have more ownership in QDEL or CERS?

Is QDEL or CERS more profitable?

Which has stronger earnings and valuation, QDEL or CERS?

Do analysts rate QDEL or CERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools